ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2309

Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study

Seth Lederman1, R Michael Gendreau2, Daniel J. Clauw3, Lesley M. Arnold4, Judith Gendreau5, Bruce Daugherty5 and Amy Forst6, 1Research and Development, Tonix Pharmaceuticals, Inc., New York, NY, 2Gendreau Consulting LLC, Poway, CA, 3Anesthesiology, University of Michigan, Ann Arbor, MI, 4Psychiatry, University of Cincinnati, Cincinnati, OH, 5Tonix Pharmaceuticals, New York, NY, 6Clinical Development, Tonix Pharmaceuticals, San Jose, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: fibromyalgia, pain, pain management, sleep disorders and therapy

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain and sleep disturbance.  Treatments that improve sleep quality in FM patients may improve fibromyalgia by a mechanism distinct from centrally acting analgesics.  TNX-102 SL1is a proprietary eutectic sublingual (SL) tablet formulation of low-dose cyclobenzaprine HCl (2.8 mg) designed for rapid absorption and long-term bedtime use.  This double-blind, randomized, placebo-controlled multicenter study (BESTFIT) evaluated the safety and efficacy of TNX-102 SL in FM.

Methods: A total of 205 patients who met ACR 2010 FM criteria were enrolled at 17 sites in a 12-week, double-blind, placebo-controlled trial. Patients were randomized 1:1 to receive TNX-102 SL (N=103) or placebo (N=102).   Outcome measures included daily pain and sleep diaries (0-10 NRS averaged over each week), Fibromyalgia Impact Questionnaire (FIQ-R), Patient Global Impression of Change (PGIC), and PROMIS Sleep Disturbance scale (PROMIS).  Data were analyzed by mean change from baseline using Mixed Effects Model Repeated Measures (MMRM) unless otherwise noted.

Results: Patients treated with TNX-102 SL showed improvement in multiple domains of FM.  Responder analysis of week 12 daily diary pain (with =>30% improvement from baseline defined as response) was statistically significant with a 34.0% pain response rate compared to 20.6% for placebo; p = 0.033.  This same pain diary data showed a decrease in pain by -1.5 compared to -1.0 for placebo; p = 0.086. Pain scores reported during clinic visits (7 day recall NRS) showed significant improvement (p = 0.033) as did the pain item on the FIQ-R (7 day recall), p = 0.004.  

TNX-102 SL improved the FIQ-R total score by -15.6 compared to -8.5 for placebo, p = 0.014. PGIC response rate(responses of 1 or 2 on a 7 point Likert Scale) was improved vs. placebo (30.1% vs. 16.7%, p = 0.025 by logistic regression).  All measures of sleep quality improved, including PROMIS sleep disturbance with an -9.0 improvement on TNX-102 SL compared to -5.1 on placebo, p = 0.005.  Sleep as measured by daily diary (change from baseline) was improved by -1.9 compared to -0.9 on placebo; p = <0.001, and the sleep quality item on the FIQ-R improved by -2.9 compared to -1.1 on placebo; p <0.001. 

Systemic adverse events (AEs) were infrequent, no item was reported in >5% of TNX-102 SL- treated patients and were similar to the placebo-treated patients.  Local administration site reactions (transient tongue or sublingual numbness) were commonly reported, occurring in approximately 42% of treated patients.  Only 3 patients withdrew from participation in the study due to local adverse events. 86% of TNX-102 SL treated patients completed versus 83% on placebo.

Conclusion: Bedtime TNX-102 SL improved sleep quality by several measures and also improved multiple other symptoms and domains of FM.  Nonrestorative sleep has been linked to central sensitization, which is characterized by changes in central pain processing.  Together these findings suggest that sleep quality is a target of therapy in FM and TNX-102 SL improvement in sleep quality was well tolerated was associated with broad symptomatic improvement.

1TNX-102 SL is an Investigational New Drug and has not been approved for any indication.


Disclosure: S. Lederman, Tonix Pharmaceuticals, 1,Tonix Pharmaceuticals, 3,Tonix Pharmaceuticals, 6; R. M. Gendreau, Tonix Pharmaceuticals, 1,Tonix Pharmaceuticals, 3,Tonix Pharmaceuticals, 5; D. J. Clauw, Pfizer Inc, 9,Lilly, 5,Tonix, 5,Cerephex, 5,Zynerba, 5,IMC, 5,Samumed, 5,Regeneron, 5; L. M. Arnold, Tonix Pharmaceuticals, 9; J. Gendreau, Tonix Pharmaceuticals, 1,Tonix Pharmaceuticals, 3; B. Daugherty, Tonix Pharmaceuticals, 1,Tonix Pharmaceuticals, 3; A. Forst, Tonix Pharmaceuticals, 1,Tonix Pharmaceuticals, 3,Tonix Pharmaceuticals, 5.

To cite this abstract in AMA style:

Lederman S, Gendreau RM, Clauw DJ, Arnold LM, Gendreau J, Daugherty B, Forst A. Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/bedtime-rapidly-absorbed-sublingual-cyclobenzaprine-tnx-102-sl-for-the-treatment-of-fibromyalgia-results-of-a-phase-2b-randomized-double-blind-placebo-controlled-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bedtime-rapidly-absorbed-sublingual-cyclobenzaprine-tnx-102-sl-for-the-treatment-of-fibromyalgia-results-of-a-phase-2b-randomized-double-blind-placebo-controlled-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology